Brought to you by 
Icagen nets $40.1mm with IPO
24 Mar 2022
Executive Summary
Drug discovery and development company Icagen (focuses on orally administered ion chanel modulators) netted about $40.1mm with its IPO of 5.1mm common shares (including the overallotment) priced at $8 each (below the $10-12 range it set last month). The company originally filed in April 2004 to raise up to $86.3mm.
Deal Industry
- Pharmaceuticals
-
Biotechnology
-
Drug Discovery Tools
- Genomics-Proteomics
- Molecular Diversity
-
Drug Discovery Tools
Deal Status
- Final
Deal Type
-
Financing
- IPO
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Icagen nets $40.1mm with IPO
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice